Skip to content
10-Q

Quarterly Report

Denali Therapeutics Inc. DNLI

0001714899-26-000064

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 158.71M sh
Shares Diluted Q1 2026 · Mar 31, 2026 186.64M sh
Shares Diluted Q1 2026 · Mar 31, 2025 171.22M sh
Capex Q1 2026 · Mar 31, 2026 $2.47M
Capex Q1 2026 · Mar 31, 2025 $5.08M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$131.2M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$131.47M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $387.63M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $205.33M
Stockholders Equity Q1 2026 · Mar 31, 2026 $926.1M
Stockholders Equity Q1 2026 · Dec 31, 2025 $1.01B
Stockholders Equity Q1 2026 · Mar 31, 2025 $1.12B
Stockholders Equity Q1 2026 · Dec 31, 2024 $1.23B
Current Liabilities Q1 2026 · Mar 31, 2026 $110.16M
Current Liabilities Q1 2026 · Dec 31, 2025 $98.35M
Total Liabilities Q1 2026 · Mar 31, 2026 $339.93M
Total Liabilities Q1 2026 · Dec 31, 2025 $131.09M
Current Assets Q1 2026 · Mar 31, 2026 $1.02B
Current Assets Q1 2026 · Dec 31, 2025 $900.66M
Total Assets Q1 2026 · Mar 31, 2026 $1.27B
Total Assets Q1 2026 · Dec 31, 2025 $1.14B
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.69
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.78
Eps Basic Q1 2026 · Mar 31, 2026 −$0.69
Eps Basic Q1 2026 · Mar 31, 2025 −$0.78
Sga Expense Q1 2026 · Mar 31, 2026 $33.51M
Sga Expense Q1 2026 · Mar 31, 2025 $29.35M
Rd Expense Q1 2026 · Mar 31, 2026 $103.85M
Rd Expense Q1 2026 · Mar 31, 2025 $116.23M
Net Income Q1 2026 · Mar 31, 2026 −$128.45M
Net Income Q1 2026 · Mar 31, 2025 −$132.97M
Operating Income Q1 2026 · Mar 31, 2026 −$137.36M
Operating Income Q1 2026 · Mar 31, 2025 −$145.58M